Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry.
Min Jung KimSun-Kyung LeeSohee OhHyoun-Ah KimYong-Beom ParkShin-Seok LeeTae-Jong KimPublished in: Rheumatology and therapy (2022)
This real-world study suggests that abatacept may have better clinical response compared to TNFi in patients with established ACPA-positive RA, especially in those that were biologics-naïve.